SVCM
CADL icon

Saturn V Capital Management’s Candel Therapeutics CADL Stock Holding History

Saturn V Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.2M Buy
+2,896,588
New +$15.8M 2.57% 15

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return

Saturn V Capital Management's CADL Position: Q1 2026 in Review

Saturn V Capital Management opened a new position in Candel Therapeutics (CADL) in Q1 2026: 2,896,588 shares worth $14.2M. The stake represents 2.57% of the portfolio and ranks #15 among its holdings.

114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Saturn V Capital Management held 2,896,588 shares of Candel Therapeutics worth $14.2M as of Q1 2026.
  • Candel Therapeutics was a new Saturn V Capital Management position in Q1 2026.
  • Candel Therapeutics made up 2.57% of Saturn V Capital Management's portfolio in Q1 2026, its #15 holding.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.